Jpmorgan Chase & CO Aerie Pharmaceuticals Inc Transaction History

Jpmorgan Chase & CO

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$6.37 - $15.23 $3.41 Million - $8.14 Million	534,754 Added 1954.94%	562,108 $8.5 Million
Q2 2022 Aug 11, 2022	BUY	$4.95 - $9.16 $7,192 - $13,309	1,453 Added 5.61%	27,354 $205,000
Q1 2022 May 11, 2022	BUY	$5.64 - $9.8 $28,701 - $49,872	5,089 Added 24.45%	25,901 $236,000
Q4 2021 Feb 10, 2022	SELL	$7.02 - $13.33 $65,236 - $123,875	-9,293 Reduced 30.87%	20,812 $146,000
Q3 2021 Nov 12, 2021	BUY	$11.32 - $16.63 $340,788 - $500,646	30,105 New	30,105 $344,000

2.4M

Ticker AERI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 49,390,500
Description
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular p...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.